Table 5 MBL2 diplotypes and odds ratio for risk of being HCV RNA negative among injection drug users
From: MBL2and Hepatitis C Virus Infection among Injection Drug Users
European Americans | African Americans | |||||||
|---|---|---|---|---|---|---|---|---|
Diplotype | HCV RNA Negative | HCV RNA Positive | OR (95% CI) | OR (95% CI)* | HCV RNA Negative | HCV RNA Positive | OR (95% CI) | OR (95% CI)* |
YA/YA | 32.1% | 37.8% | 1.00 | 1.00 | 30.3% | 31.3% | 1.00 | 1.00 |
XA/YA | 25.7% | 22.7% | 1.36 (0.77–2.43) | 1.36 (0.77–2.43) | 18.0% | 18.1% | 1.01 (0.50–2.05) | 1.01 (0.50–2.05) |
YA/YO | 16.5% | 24.1% | 0.81 (0.43–1.55) | 0.99 (0.77–1.79) | 29.2% | 31.0% | 0.96 (0.52–1.78) | 1.00 (0.55–1.83) |
XA/XA | 5.5% | 2.3% | 2.74 (0.88–8.52) | 2.3% | 1.3% | 2.08 (0.35–12.21) | ||
XA/YO | 12.8% | 7.3% | 2.31 (1.07–5.02) | 2.00 | 7.9% | 10.0% | 0.82 (0.33–2.08) | 1.13 |
YO/YO | 7.3% | 5.8% | 1.61 (0.65–4.03) | (1.05–3.82) | 12.4% | 8.4% | 1.49 (0.65–3.41) | (0.57–2.24) |